“Two-in-One” approach for bioassay selection for dual specificity antibodies

Journal of Immunological Methods

Volumn 448, Issue , 2017, Pages 74-79

  Lee, Ho Young ^a   Schaefer, Gabriele ^a   Lesaca, Ingrid ^a   Lee, Chingwei Vivian ^a   Wong, Pin Yee ^a   Jiang, Guoying ^a  

^a GENENTECH INC   (United States)

Author keywords

Binding assay; Bioassay; Bispecific antibody; Cell proliferation; Dual specific antibody; Signaling pathways

Indexed keywords

BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; HER3 PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; ANTIGEN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB3 PROTEIN, HUMAN; PROTEIN BINDING;

ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BIOASSAY; CELL PROLIFERATION ASSAY; COMPLEMENTARITY DETERMINING REGION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIMERIZATION; EC50; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LIGAND BINDING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; PROTEIN TARGETING; RECEPTOR BINDING; RECEPTOR BINDING ASSAY; SIGNAL TRANSDUCTION; TWO IN ONE BIOASSAY; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PROCEDURES; REPRODUCIBILITY;

ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTIGENS; BINDING SITES, ANTIBODY; BIOLOGICAL ASSAY; CELL LINE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUTATION; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 85020481591     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2017.05.011     Document Type: Article

References (13)

1. Beck, A., Wurch, T., Bailly, C., Corvaia, N., PersPectIves. Nat. Rev. Immunol. 10 (2010), 345–352, 10.1038/nri2747.
2. Gao, J., Chesebrough, J.W., Cartlidge, S.A., Ricketts, S.A., Incognito, L., Veldman-Jones, M., Blakey, D.C., TABRIZI, M., Jallal, B., Trail, P.A., Coats, S., Bosslet, K., Chang, Y.S., Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res. 71 (2011), 1029–1040, 10.1158/0008-5472.CAN-10-2274.
3. Garber, K., News & analysis. Nat. Publ. Group 13 (2014), 799–801, 10.1038/nrd4478.
4. Huang, S., Armstrong, E.A., Benavente, S., Chinnaiyan, P., Harari, P.M., Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64 (2004), 5355–5362, 10.1158/0008-5472.CAN-04-0562.
5. Huang, S., Li, C., Armstrong, E.A., Peet, C.R., Saker, J., Amler, L.C., Sliwkowski, M.X., Harari, P.M., Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73 (2013), 824–833, 10.1158/0008-5472.CAN-12-1611.
6. Hynes, N.E., MacDonald, G., ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21 (2009), 177–184, 10.1016/j.ceb.2008.12.010.
7. Ignar-Trowbridge, D.M., Nelson, K.G., Bidwell, M.C., Curtis, S.W., Washburn, T.F., McLachlan, J.A., Korach, K.S., Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. 89 (1992), 4658–4662.
8. James, L.C., Roversi, P., Tawfik, D.S., Antibody multispecificity mediated by conformational diversity. Science (New York, N.Y.) 299 (2003), 1362–1367.
9. Kontermann, R., Dual targeting strategies with bispecific antibodies. MAbs 4 (2014), 182–197, 10.4161/mabs.4.2.19000.
10. Mariuzza, R.A., Multiple paths to multispecificity. Immunity 24 (2006), 359–361, 10.1016/j.immuni.2006.03.009.
11. Neve, R.M., Lane, H.A., Hynes, N.E., The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J., 2000.
12. Rouet, R., Christ, D., News and views. Nat. Publ. Group 32 (2014), 136–137, 10.1038/nbt.2812.
13. Schaefer, G., Haber, L., Crocker, L.M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C.V., Stawicki, S., Clark, R., Fields, C., Phillips, G.D.L., Prell, R.A., Danilenko, D.M., Franke, Y., Stephan, J.-P., Hwang, J., Wu, Y., Bostrom, J., Sliwkowski, M.X., Fuh, G., Eigenbrot, C., A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20 (2011), 472–486, 10.1016/j.ccr.2011.09.003.